Literatur
-
1
Bennett M R.
Reactive
oxygen species and death. Oxidative DNA damage in atherosclerosis.
Circulation
Res.
2001;
88
648-651
-
2
Bhakdi S, Dorweiler B, Kirchmann R. et al .
On
the pathogenesis of atherosclerosis: Enzymatic transformation of
human low density lipoprotein to an atherogenic moiety.
J
Exp Med.
1995;
182
1959-1971
-
3
Bhakdi S, Torzewski M, Klouche M, Hemmes M.
Complement
and atherogenesis: binding of CRP to degraded non-oxidized LDL enhances
complement activation.
Arterioscler Thromb Vasc Biol.
1999;
19
2348-2354
-
4
Bhakdi S.
Complement
and atherosclerosis: the unknown connection.
Ann Med.
1998;
30
503-507
-
5
Blackburn R, Giral P, Bruckert E. et al .
Elevated C-reactive protein constitutes
an independent predictor of advanced carotid plaques in dyslipidemic
subjects.
Arterioscler Thromb Vasc Biol.
2001;
21
1962-1968
-
6
Blake G J, Ridker P M.
Novel clinical
markers of vascular wall inflammation.
Circulation Res.
2001;
89
763-771
-
7
Brown B G, Zhao X Q, Chait A. et al .
Simvastatin and niacin, antioxidant vitamins,
or the combination for the prevention of coronary disease.
N Engl
J Med.
2001;
345
1583-1592
-
8
Chao F F, Amende L M, Blanchette Mackie E J. et al .
Unesterified cholesterol-rich lipid particles
in atherosclerotic lesions of human and rabbit aortas.
Am
J Pathol.
1988;
131
73-83
-
9
Cleeman J I.
corresponding
author for the Expert Panel on Detection, Evaluation, and Treatment
of high blood cholesterol in adults (Adult treatment panel III).
Executive summary of the third report of the National Cholesterol
Education Program (NCEP).
JAMA.
2001;
285
2468-2496
-
10
Frank J S, Fogelman A M.
Ultrastructure
of the intima in WHHL and cholesterol-fed rabbit aortas prepared
by ultrarapid freezing and freeze-etching.
J Lipid Res.
1989;
30
967-978
-
11
Freedman J E.
Antioxidants
versus lipid-altering therapy - some answers, more questions.
N
Engl J Med.
2001;
345
1636-1637
-
12
Glass C K, Witztum J.
Atherosclerosis.
Cell.
2001;
104
503-516
-
13
Goldstein J L, Brown M.
The cholesterol quartet.
Science.
2001;
292
1310-1312
-
14
Griendling K K, Harrison D G.
Out, damned
dot: studies of the NADPH oxidase in atherosclerosis.
J
Clin Invest.
2001;
108
1423-1424
-
15
Kearny J F.
Immune
recognition of ox-LDL in atherosclerosis.
J Clin Invest.
2000;
105
1683-1685
-
16
Klouche M, Gottschling S, Gerl V. et al .
Atherogenic properties of enzymatically
degraded LDL Selective induction of MCP-1 and cytotoxic effects
on human macrophages.
Arterioscler Thromb Vasc Biol.
1998;
18
1376-1385
-
17
Kruth H S.
Localization
of unesterified cholesterol in human atherosclerotic lesions.
Am
J Pathol.
1984;
114
201-208
-
18
Kruth H S.
Subendothelial
accumulation of unesterified cholesterol.
Atherosclerosis.
1985;
57
337-341
-
19
Kühn H, Heydeck D, Hugou I, Gniwotta C.
In vivo action of 15-lipoxy-genase
in early stages of human atherogenesis.
J Clin Invest.
1997;
99
888-893
-
20
Lehr H A, Sagban T A, Ihlig C. et al .
Immunopathogenesis of atherosclerosis Endotoxin
accelerates atherosclerosis in rabbits on hypercholesterolemic diet.
Circulation.
2001;
104
914-920
-
21
Lusis A J.
Atherosclerosis.
Nature.
2000;
407
233-241
-
22
Niculescu F, Hugo F, Rus H G, Vlaicu R, Bhakdi S.
Quantitative
evaluation of the terminal C5b-9 complement complex by ELISA in
human atherosclerotic arteries.
Clin Exp Immunol.
1987;
69
477-483
-
23
Rabelink T J, Stroes E.
Atherosclerosis. Defeat
of the Defense?.
Circulation Res.
2001;
88
456-459
-
24
Schmiedt W, Kinscherf R, Deigner H P. et al .
Complement C6 deficiency protects against
diet-induced atherosclerosis in rabbits.
Arterioscler Thromb
Vasc Biol.
1998;
18
1790-1795
-
25
Schultz D, Harrison D G.
Quest for
fire. Seeking the source of pathogenic oxygen radicals in atherosclerosis.
Arterioscler
Thromb Vasc Biol.
2000;
20
1412-1415
-
26
Seifert P S, Hugo F, Hansson G K, Bhakdi S.
Prelesional complement
activation in experimental atherosclerosis Terminal C5b-9 complement deposition
coincides with cholesterol accumulation in the aortic intima of
hypercholesterolemic rabbits.
Lab Invest.
1989;
60
747-754
-
27
Seifert P S, Hugo F, Tranum-Jensen J, Zahringer U, Muhly M, Bhakdi S.
Isolation and characterization
of a complement-activating lipid extracted from human atherosclerotic
lesions.
J Exp Med.
1990;
172
547-557
-
28
Simionescu N, Vasile E, Lupu F, Popescu G, Simionescu M.
Prelesional events
in atherogenesis: accumulation of extracellular cholesterol-rich liposomes
in the arterial intima and cardiac valves of the hyperlipidemic
rabbit.
Am J Pathol.
1986;
123
109-125
-
29
Steinberg D, Parthasarathy S, Carew T E, Khoo J C, Witztum J L.
Beyond cholesterol:
modifications of low-density lipoprotein that increase its atherogenicity.
N
Engl J Med.
1989;
320
915-924
-
30
Steinbrecher U P, Parthasarathy S, Leake D S, Witztum J L, Steinberg D.
Modification
of low density lipoprotein by endothelial cells involves lipid peroxidation
and degradation of low density lipoprotein phospholipids.
Proc
Natl Acad Sci USA.
1984;
81
3883-3887
-
31
Takemoto M, Liao J K.
Pleiotropic effects
of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors.
Arterioscler
Thromb Vasc Biol.
2001;
21
1712-1719
-
32
Torzewski M, Klouche M, Hock J. et al .
Immunohistochemical demonstration of enzymatically
modified human LDL in its colocalization with the terminal complement
complex in the early atherosclerotic lesion.
Arterioscler
Thromb Vasc Biol.
1998;
18
369-378
-
33
Vlaicu R, Niculescu F, Rus H G, Christea A.
Immunohistochemical
localization of the terminal C5b-9 complement complex in human aortic
fibrous plaque.
Atherosclerosis.
1985;
57
163-167
Prof. Dr. Sucharit Bhakdi
Institut für Medizinische Mikrobiologie und
Hygiene der Johannes Gutenberg-Universität Mainz
Hochhaus am Augustusplatz
55101 Mainz
Fax: 06131/3932359
eMail: sbhakdi@mail.uni-mainz.de
